MENU
+Compare
GDTC
Stock ticker: NASDAQ
AS OF
Jun 6 closing price
Price
$2.05
Change
+$0.03 (+1.49%)
Capitalization
23.31M

GDTC CytoMed Therapeutics Limited Forecast, Technical & Fundamental Analysis

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers... Show more

GDTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GDTC with price predictions
May 16, 2025

GDTC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for GDTC turned positive on May 14, 2025. Looking at past instances where GDTC's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GDTC advanced for three days, in of 85 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GDTC as a result. In of 38 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDTC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GDTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.351) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (434.783) is also within normal values, averaging (268.270).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GDTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GDTC is expected to report earnings to fall 66.67% to -3 cents per share on May 28

CytoMed Therapeutics Limited GDTC Stock Earnings Reports
Q1'25
Est.
$-0.04
Q4'24
Missed
by $0.08
Q3'24
Est.
$-0.04
Q2'24
Beat
by $0.01
Q1'24
Est.
$-0.04
The last earnings report on May 05 showed earnings per share of -11 cents, missing the estimate of -3 cents. With 8.21K shares outstanding, the current market capitalization sits at 23.31M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Commonwealth Lane
Phone
+65 62507738
Employees
28
Web
https://w2.cytomed.sg
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

GDTC and Stocks

Correlation & Price change

A.I.dvisor tells us that GDTC and CVKD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GDTC and CVKD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GDTC
1D Price
Change %
GDTC100%
-3.08%
CVKD - GDTC
31%
Poorly correlated
-2.04%
CYCN - GDTC
31%
Poorly correlated
-5.78%
ADIL - GDTC
30%
Poorly correlated
+1.49%
QSI - GDTC
26%
Poorly correlated
-7.29%
JSPR - GDTC
26%
Poorly correlated
+7.13%
More